(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Exclusive-Head of Pemex's production arm to step down in coming days, sources say - 2Partake in the Outside: Senior-Accommodating Exercises for 2024
- 3Study finds humans were making fire 400,000 years ago, far earlier than once thought
- 4The best overlooked performances of 2025
- 5How did I get my own unique set of fingerprints?
- Holiday spots Well known With Americans In 2024
- The top astronomical discoveries of 2025
- Russia accidentally destroys its only way of sending astronauts to space
- Instructions to Figure out the Various Phases of Cellular breakdown in the lungs
- Alice Wong, founder of the Disability Visibility Project, dies at 51
- Nigeria police charge Joshua driver with dangerous driving over fatal crash
- Flourishing in a Remote Workplace: Individual Techniques
- The Most Rousing Ladies Business visionaries of Today
- Courageous Climbing: Trails and Stuff for Outside Lovers
